HSE pays 47% more for 'brand name' drugs

A new survey has found that Ireland's Health Service is paying one-and-a-half times more than Britain for brand name medicines.

HSE pays 47% more for 'brand name' drugs

A new survey has found that Ireland's Health Service is paying one-and-a-half times more than Britain for brand name medicines.

The study carried out for the Swedish pharmaceutical sector shows that Ireland pays more than any other Northern European country for drugs that are still under patent.

You have reached your article limit. Already a subscriber? Sign in

Continue reading for €5

Unlock unlimited access and exclusive benefits

More in this section

Lunchtime News

Newsletter

Keep up with stories of the day with our lunchtime news wrap and important breaking news alerts.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited